Structural diversity of peroxisome proliferators and their effects on mammalian liver cells in vivo

Annals of the New York Academy of Sciences

Volumn 804, Issue , 1996, Pages 310-327

  De La Iglesia, Felix A ^a   McGuire, Edward J ^a   Haskins, Jeffrey R ^a   Lalwani, Narendra D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; LIPID; LIPOPROTEIN; MEMBRANE PROTEIN; PEROXISOME PROLIFERATOR;

AREA UNDER THE CURVE; CONFERENCE PAPER; DRUG SAFETY; DRUG STRUCTURE; HUMAN; LIPID METABOLISM; LIVER CELL; NONHUMAN; PEROXISOME; PROTEIN SYNTHESIS; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION;

MAMMALIA;

EID: 0030468075     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb18625.x     Document Type: Conference Paper

References (35)

1. HESS, R., W. STÄUBLI & W. RIESS. 1965. Nature of the hepatomegalic effect produced by ethyl-chlorophenoxyisobutyrate in the rat. Nature (London) 208:856-858
2. FAHIMI, H. D., E. BAUMGART, K. BEIER, J. PILL, F. HARTIG & A. VÖLKL. 1993. Ultrastructural and biochemical aspects of peroxisome proliferation and biogenesis in different mammalian species. In Peroxisomes: Biology and Importance in Toxicology and Medicine. G. Gibson & B. Lake, Eds.: 395-424. Taylor and Francis, London.
3. MCGUIRE, E. J., J. A. LUCAS, R. H. GRAY & F. A. DE LA IGLESIA. 1991. Peroxisome induction potential and lipid-regulating activity in rats. Quantitative microscopy and chemical structure-activity relationships. Am.J. Pathol. 139(1): 217-229.
4. LAZAROW, P. B. & C. DEDUVE. 1976. A fatty acyl-CoA oxidizing system in rat liver peroxisomes: Enhancement by clofibrate, a hypolipidemic drug. Proc. Natl. Acad. Sci. USA 73: 2043-2046.
5. LAZAROW, P. B., H. SHIO & M. A. LEROY-HOUYET. 1982. Specificity in the action of hypolipidemic drugs: Increase of peroxisomal B-oxidation largely dissociated from hepatomegaly and peroxisome proliferation in the rat. J. Lipid Res. 23: 317-326.
6. REDDY, J. K., J. R. WARREN, M. K. REDDY & N. D. LALWANI. 1982. Hepatic and renal effects of peroxisome proliferators: Biological implications. Ann. N.Y. Acad. Sci. 386: 81-108.
7. FAHIMI, H. D., A. REINICKE, M. SUJATTA, S. YOKOTA , M. ÖZEL, F. HARTIG & K. STEGMEIER. 1982. The short- and long-term effects of bezafibrate in the rat. Ann. N .Y. Acad. Sci. 386:111-135.
8. DE LA IGLESIA, F. A. & E. J. MCGUIRE. 1981. Quantitative stereology: Toxicologic pathology applications. Toxicol. Pathol. 9: 21-28.
9. DE LA IGLESIA, F. A., R. H. GRAY & E. J. MCGUIRE. 1992. Subcellular organelle biogenesis and dynamics in peroxisome proliferation. J. Amer. Coll. Toxicol. 11(3): 343-348.
10. RAO, M. S. & J. K. REDDY. 1987. Peroxisome proliferation and hepatocarcinogenesis. Carcinogenesis 8: 631-636.
11. REDDY, J. K. & N. D. LALWANI. 1984. Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. CRC Crit. Rev. Toxicol. 12: 1-58.
12. LINDAUER, M., K. BEIER, A. VÖLKL & H. D. FAHIMI. 1994. Zonal heterogeneity of peroxisomal enzymes in rat liver: Differential induction by three divergent hypolipidemic drugs. Hepatology 20(2): 475-486.
13. LAZAROW, P. 1993. Genetic approaches to studying peroxisome biogenesis. Trends in Cell Biology 3: 89-93.
14. LAZAROW, P. B., M. ROBBI, Y. FUJIKI & L. WONG. 1982. Biogenesis of peroxisomal proteins in vivo and in vitro. Ann. N. Y. Acad. Sci. 386: 285-300.
15. DEDUVE, C., P. B. LAZAROW & B. POOLE. 1974. Biogenesis and turnover of rat-liver peroxisomes. In Advances in Cytopharmacology 2. B. Ceccarelli, F. Clementi & J. Meldolesi, Eds.: 219-223. Raven Press. New York.
16. RODRICKS, J. V. & D. TURNBULL. 1987. Interspecies differences in peroxisomes and peroxisome proliferation. Toxicol. Ind. Health 3: 197-212.
17. STERNLIEB, I. 1979. Electron microscopy of mitochondria and peroxisomes of human hepatocytes. In Progress in Liver Diseases, vol. 6. H. Popper & F. Schaffner, Eds.: 81-104. Grune and Stratton. New York.
18. GRAY, R. H. & F. A. DE LA IGLESIA. 1984. Quantitative microscopy comparison of peroxisome proliferation by the lipid-regulating agent gemfibrozil in several species. Hepatology 4: 520-530.
19. DE LA IGLESIA, F. A., J. E. LEWIS, R. A. BUCHANAN, E. L. MARCUS & G. MACMAHON. 1982. Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis 43: 19-37.
20. DE LA IGLESIA, F. A., J. M. STURGESS & G. FEUER. 1982. New approaches for the assessment of hepatotoxicity by means of quantitative functional-morphological interrelationships. In Toxicology of the Liver. G. Plaa & R. W. Hewitt, Eds.: 47-102. Raven Press, New York.
21. GRAY, R. H., E. J. MCGUIRE, J. A. LUCAS & F. A. DE LA IGLESIA. 1984. Comparative study of peroxisome proliferation by gemfibrozil in two strains of hamsters. Fed. Proc. 43: 384.
22. KEMMER, C. & M. HANEFELD. 1977. Ultrastructural findings in liver biopsies from patients with hyperlipoproteinemia. Zentralbl. Allg. Pathol. 121: 243-253.
23. VOSS, K. & C. KEMMER. 1978. Image processing in pathology. VIII. Internal structure of mitochondria during treatment of HLP-patients with Regadrin. Exp. Pathol. 15: 311-318.
24. SCHWANDT, P., O. KLINGE & H. IMMICH. 1978. Clofibrate and the liver. Lancet 2(8084): 325.
25. HANEFELD, M., C. KEMMER, W. LEONHARDT, K. D. KUNZE, W. JAROSS & H. HALLER. 1980. Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver. Atherosclerosis 36(2): 159-172.
26. HANEFELD, M., C. KEMMER & E. KADNER. 1983. Relationship between morphological changes and lipid-lowering action of p-chlorophenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis 46(2): 239-246.
27. GARIOT, P., E. BARRAT, L. MEJEAN, J. P. POINTEL, P. DROUIN & G. DEBRY. 1983. Fenofibrate and human liver: Lack of proliferation of peroxisomes. Arch. Toxicol. 53(2): 151-163.
28. GARIOT, P., E. BARRAT, P. DROUIN, P. GENTON, J. P. POINTEL, B. FOLIGUET, M. KOLOPP & G. DEBRY. 1987. Morphometric study of human hepatic cell modifications induced by fenofibrate. Metabolism 36(3): 203-210.
29. CAMERON, R. G., F. A. DE LA IGLESIA & G. FEUER. 1996. Hepatotoxicity of cardiovascular drugs. In Drug-Induced Hepatotoxicity. R. G. Cameron, G. Feuer & F. A. De la Iglesia, Eds.: 477-513. Springer-Verlag, Heidelberg.
30. NEWTON, R. S. & B. R. KRAUSE. 1986. Mechanisms of action of gemfibrozil: Comparison of studies in the rat to clinical efficacy. In Pharmacological Control of Hyperlipidaemia: 171-186. J. R. Prous Science Publishers. Barcelona.
31. LAKE, B. G. & D. F. V LEWIS. 1993. Structure-activity relationships for chemically induced peroxisome proliferation in mammalian liver. In Peroxisomes. Biology and Importance in Toxicology and Medicine. G. Gibson & B. Lake, Eds.: 313-342. Taylor and Francis. London.
32. MORIN, M. J., L. M. ANDRE, K. ALVARES & J. K. REDDY. 1987. Lack of activation of protein kinase C. and protein phosphorylation by ciprofibrate, a carcinogenic peroxisome proliferator. Proc. Annu. Meet. Am. Assoc. Cancer Res. 28: 152.
33. LALWANI, N. D., K. ALVARES, M. K. REDDY, M. N. REDDY, I. PARIKH & J. K. REDDY. 1987. Peroxisome proliferator-binding protein: Identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver. Proc. Natl. Acad. Sci. USA 84: 5242-5246.
34. MCGUIRE, E. J., R. H. GRAY & F. A. DE LA IGLESIA. 1992. Chemical structure-activity relationships: Peroxisome proliferation and lipid regulation in rats. J. Am. Coll. Toxicol. 11(3): 353-361.
35. GOTTO, A. M. JR. 1993. Dyslipidemia and atherosclerosis: A forecast of pharmaceutical approaches. Circulation 87(Suppl.) III54-III59.